Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education
Dementia and Geriatric Cognitive Disorders · 2024
DOI: 10.1159/000538630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders, 2024. Verfasst von Lucas Nogueira de Carvalho Pelegrini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gerontology, Federal University of São Carlos, São Carlos, Brazil. Hauptthemen laut MEDLINE: ADAM10 Protein, Alzheimer Disease, Cognitive Dysfunction, Educational Status. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Gerontologische Pflege, Demenz
Abstract (Originalsprache)
Introduction
Low educational attainment is a potential risk factor for Alzheimer’s disease (AD) development. Alpha-secretase ADAM10 plays a central role in AD pathology, attenuating the formation of beta-amyloid peptides and, therefore, their aggregation into senile plaques. This study seeks to investigate ADAM10 as a blood-based biomarker in mild cognitive impairment (MCI) and AD in a diverse group of community-dwelling older adults, focusing on those with limited educational attainment.
Methods
Participants were recruited from public health services. Cognition was evaluated using Mini-Mental State Examination (MMSE) and Addenbrooke’s Cognitive Examination – Revised (ACE-R) batteries. Blood samples were collected to analyze plasma ADAM10 levels. A logistic regression was conducted to verify the influence of plasma ADAM10 on the AD diagnosis.
Results
Significant differences in age, years of education, prescribed medications, and cognitive test scores were found between the MCI and AD groups. Regarding cognitive performance, both ACE-R and MMSE scores displayed significant differences between groups, with post hoc analyses highlighting these distinctions, particularly between AD and cognitively unimpaired individuals. Elevated plasma ADAM10 levels were associated with a 4.5-fold increase in the likelihood of a diagnosis of MCI and a 5.9-fold increase in the likelihood of a diagnosis of AD. These findings suggest ADAM10 levels in plasma as a valuable biomarker for assessing cognitive status in older individuals with low education attainment.
Conclusion
This study underscores the potential utility of plasma ADAM10 levels as a blood-based biomarker for cognitive status, especially in individuals with low educational backgrounds, shedding light on their relevance in AD development and diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gerontology, Federal University of São Carlos, São Carlos, Brazil.
- Pharmaceutical Sciences Faculty, University of São Paulo, São Paulo, Brazil.
- Department of Gerontology, Federal University of São Carlos, São Carlos, Brazil, mcominetti@ufscar.br.
- Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, mcominetti@ufscar.br.
Zitieren
APA
Pelegrini, L. N. C., da Silva, V. A., Grigoli, M. M., Vatanabe, I. P., Manzine, P. R., & Cominetti, M. R. (2024). Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000538630
Vancouver
Pelegrini LNC, da Silva VA, Grigoli MM, Vatanabe IP, Manzine PR, Cominetti MR. Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education. Dementia and Geriatric Cognitive Disorders. 2024. doi:10.1159/000538630
BibTeX
@article{Pelegrini2024,
author = {Pelegrini, Lucas Nogueira de Carvalho and da Silva, Vanessa Alexandre and Grigoli, Marina Mantellatto and Vatanabe, Izabela Pereira and Manzine, Patricia Regina and Cominetti, Marcia Regina},
title = {Plasma ADAM10 Levels and Their Association with Alzheimer’s Disease Diagnosis in Older Adults with Fewer Years of Formal Education},
journal = {Dementia and Geriatric Cognitive Disorders},
year = {2024},
doi = {10.1159/000538630}
}
EUVIMED